Irene Bolea

Irene Bolea

Auto-generated profile, based on publicly available information

Irene Bolea

Departament de Bioquímica i Biologia Molecular, Facultat de Medicina, Institut de Neurociències, Universitat Autònoma de Barcelona Barcelona, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 December 2012 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
IBIrene Bolea
Irene Bolea
AGAlejandro Gella
Alejandro Gella
MUMercedes Unzeta
Mercedes Unzeta


25 May 2016 in Frontiers in Neuroscience
Verified
Journal Article
Open access
MUMercedes Unzeta
Mercedes Unzeta
GEGerard Esteban
Gerard Esteban
IBIrene Bolea
Irene Bolea
WFWieslawa A. Fogel
Wieslawa A. Fogel
Rona RamsayRona Ramsay
Rona Ramsay
JMJosé Marco-Contelles
José Marco-Contelles
Alzheimer's disease (AD), the most common form of adult onset dementia, is an age-related neurodegenerative disorder characterized by progressive memory loss, decline in language skills and other cognitive impairments. Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress and neuroinflammation are considered to play significant roles in the pathophysiology of this disease. For a long time, AD patients have been treated with acetylcholinesterase inhibitors such as donepezil (Aricept®) but with limited therapeutic success. This might be due to the complex multifactorial nature of AD, a fact that has prompted the design of new Multi-Target-Directed Ligands (MTDL) based on the “one molecule, multiple targets” paradigm. Thus, in this context, different series of novel multifunctional molecules with antioxidant, anti-amyloid, anti-inflammatory and metal-chelating properties able to interact with multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase, butyrylcholinesterase and monoamine oxidases A and B have been designed and assessed biologically. This review describes the multiple targets, the design rationale and an in-house MTDL library, bearing the N-benzylpiperidine motif present in donepezil, linked to different heterocyclic ring systems (indole, pyridine or 8-hydroxyquinoline) with special emphasis on compound ASS234, an N-propargylindole derivative. The description of the in vitro biological properties of the compounds and discussion of the corresponding structure-activity-relationships allows us to highlight new issues for the identification of more efficient MTDL for use in AD therapy.

12 November 2009 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
TVTony Valente
Tony Valente
JHJuan Hidalgo
Juan Hidalgo
IBIrene Bolea
Irene Bolea
BRBartolomé Ramirez
Bartolomé Ramirez
NANeus Anglés
Neus Anglés
MUMercedes Unzeta
Mercedes Unzeta
At present it is widely accepted that there are at least two neurogenic sites in the adult mammalian brain: the subventricular zone (SVZ) of lateral ventricles and the subgranular zone (SGZ) of the hippocampus dentate gyrus. The adult proliferation r

28 June 2016 in Frontiers in Neuroscience
Verified
Journal Article
Open access
Jose Marco-ContellesJose Marco-Contelles
Jose Marco-Contelles
MUMercedes Unzeta
Mercedes Unzeta
IBIrene Bolea
Irene Bolea
GEGerard Esteban
Gerard Esteban
Rona RamsayRona Ramsay
Rona Ramsay
LILhassane Ismaili
Lhassane Ismaili
The complex nature of Alzheimer’s disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines showing antioxidant, anti-beta-amyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aβ-aggregation, possessing antioxidant and neuroprotective properties.